AndersonJ, WangC, ZaidiA, RiceT, CoffeyBJ: Guanfacine as a treatment for posttraumatic stress disorder in an adolescent female. J Child Adolesc Psychopharmacol, 30:398–401, 2020.
2.
ArnoneD: Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry, 4:1–4, 2005.
3.
BerlantJ, van KammenDP: Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. J Clin Psychiatry, 63:15–20, 2002.
4.
BerlantJ: Topiramate as a therapy for chronic posttraumatic stress disorder. Psychiatry (Edgmont), 3:40, 2006.
5.
BorzutzkyC, KingE, FoxCK, StratbuckerW, TuckerJ, YeeJK, KumarS, CudaS, SweeneyB, KirkS: Trends in prescribing anti-obesity pharmacotherapy for paediatric weight management: Data from the POWER Work Group. Pediatr Obes, 16:e12701; 2021.
6.
BrewinCR, CloitreM, HylandP, ShevlinM, MaerckerA, BryantRA, HumayunA, JonesLM, KageeA, RousseauC, SomasundaramD: A review of current evidence regarding the ICD-11 proposals for diagnosing PTSD and complex PTSD. Clin Psychol Rev, 58:1–5, 2017.
7.
CassanoP, LattanziL, PiniS, Dell'OssoL, BattistiniG, CassanoGB: Topiramate for self-mutilation in a patient with borderline personality disorder. Bipolar Disord, 3:161, 2001.
8.
CraddockN, SklarP: Genetics of bipolar disorder. Lancet, 381:1654–1662, 2013.
9.
CzepielKS, PerezNP, Campoverde ReyesKJ, SabharwalS, StanfordFC. Pharmacotherapy for the treatment of overweight and obesity in children, adolescents, and young adults in a large health system in the US. Front Endocrinol, 11:290, 2020.
de Moraes CostaG, ZanattaFB, ZiegelmannPK, BarrosAJ, MelloCF: Pharmacological treatments for adults with post-traumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability. J Psychiatr Res, 130:412–420, 2020.
12.
DoyleCA, McDougleCJ: Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother, 13:1615–1629, 2012.
13.
HsiaDS, GosselinNH, WilliamsJ, FarhatN, MarierJF, ShihW, PetersonC, SiegelR: A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity. Diabetes Obes Metab, 22: 480–491, 2020.
14.
KahathuduwaCN, WestBD, BlumeJ, DharavathN, Moustaid-MoussaN, MastergeorgeA: The risk of overweight and obesity in children with autism spectrum disorders: A systematic review and meta-analysis. Obes Rev, 20:1667–1679, 2019.
LoewTH, NickelMK, MuehlbacherM, KaplanP, NickelC, KettlerC, FartacekR, LahmannC, BuschmannW, TrittK, BachlerE: Topiramate treatment for women with borderline personality disorder: A double-blind, placebo-controlled study. J Clin Psychopharmacol, 26:61–66, 2006.
17.
LuftMJ, LamyM, DelBelloMP, McNamaraRK, StrawnJR: Antidepressant-induced activation in children and adolescents: Risk, recognition and management. Curr Probl Pediatr Adolesc Health Care, 48:50–62, 2018.
18.
NarayanaswamiV, DwoskinLP: Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther, 170:116–147, 2017.
19.
NickelMK, NickelC, MitterlehnerFO, TrittK, LahmannC, LeiberichPK, RotherWK, LoewTH: Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. J Clin Psychiatry, 65:1515–1519, 2004.
20.
MulaM, CavannaAE, MonacoF: Psychopharmacology of topiramate: From epilepsy to bipolar disorder. Neuropsychiatr Dis Treat, 2:475–488, 2006.
21.
RiceT, GrassoJ, DembarA, CaplanO, CohenA, CoffeyB: Guanfacine as a facilitator of recovery from conversion disorder in a young girl. J Child Adolesc Psychopharmacology, 28:571–575, 2018.
22.
RichardD, FerlandJ, LalondeJ, SamsonP, DeshaiesY: Influence of topiramate in the regulation of energy balance. Nutrition, 16:961–966, 2000.
